Replies to post #88884 on Amarin Corp Plc (AMRN)

[Pyrrhonian]

First of all: I stand corrected since isn't living in the US ... but OMG
- show me any plan that keep Lovaza as Tier 1 (I guess it wasn't Tier 1 ever)
- if you mean generic Lovaza (as I think ...)
a.) I am sure it isn't Tier 1 in all plan
b.) you have to know that generic and brand products tiered differently. If the brand is still exist - meanwhile generic is available - the generic has a better tier than brand. --HD

Didn't think I needed to split hairs to that degree, lol. Okay, sorry, yes Lovaza and its generics.

https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Pharmacy%20Resources/PDL_Phys_Bk.pdf

biggest in the US.

But I said you guys can have the last word, and I intend to stand by that, but looking for more color here:

a.) TG - read the AdCom slides, the Co stated de facto the TG levels for the first 6,075 patients (inc. breakdown of the app. 5,000-6,075) and it was 220.
b.) LDL-C inclusion criteria: 40-100 ... it isn't listed among risk factors

You're saying it was (mean?) 220 for the whole group, or for the 1,075 enrolled after the 5k were already enrolled?

"Elevated TG" was required for entry initially, but that means > 150. And if the mean TG of the whole is "about 200," or even exactly 220, why do you not think many patients with TG counts from 150 - 199 got into the study? Or how many do you think with mean TG counts 150 - 199 got in?

Wrt baseline EPA levels and ANCHOR or MARINE vs R-IT, do you think control in R-IT will have baseline closer to MAR or ANCH? And why? What would you guess it will be?

Thanks